they are when used in EGFR as described in QSAR studies. These show some selectivity towards IGF-1R over IR. Pyrrolo(2,3-d)-pyrimidine derivatives such as NVP-AEW541, invented by Novartis, which show far greater (100 fold) selectivity towards IGF-1R over IR. Monoclonal antibodies are probably the most specific and promising therapeutic compounds. Teprotumumab is a novel therapy showing significant benefit for Thyroid Eye Disease. Interactions Insulin-like growth factor 1 receptor has been shown to interact with: ARHGEF12, C-src tyrosine kinase, Cbl gene, EHD1, GRB10, IRS1, Mdm2, NEDD4, PIK3R3, PTPN11, RAS p21 protein activator 1, SHC1 SOCS2, SOCS3, and YWHAE. Regulation There is evidence to suggest that IGF1R is negatively regulated by the microRNA miR-7. See also Hypothalamic–pituitary–somatic axis Insulin receptor Linsitinib, an inhibitor of IGF-1R in clinical trials for cancer treatment References Further reading External links Clusters of differentiation Tyrosine kinase receptors Integral membrane proteins